Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs

    Lina Alhanshali, Michael Buontempo, Kristen I. Lo Sicco, Jerry Shapiro
    Image of study
    TLDR Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
    Alopecia Areata (AA) is a non-scarring hair loss disorder affecting 2.1% of the population, caused by an autoimmune attack on the hair follicle. The disease can spontaneously resolve but often follows a relapsing-remitting course. Treatments include topical steroids, intralesional steroids, topical immunotherapies, Janus Kinase (JAK) inhibitors, and systemic corticosteroids, with varying success rates. Topical 0.1% betamethasone valerate foam applied twice daily for 12 weeks achieved 75% hair regrowth in mild-to-moderate AA. JAK inhibitors, such as baricitinib and tofacitinib, may be effective but have potential side effects like malignancy, cardiovascular events, and gastrointestinal effects. AA significantly impacts patients' quality of life, causing increased depression, anxiety, and social functioning impairments. The document emphasizes the need for better therapeutics, improved access to treatments, and public support for people suffering from AA.
    View this study on →

    Cited in this study

    54 / NoResults


    3 / NoResults
      Linear alopecia areata

      research Linear alopecia areata

      4 citations ,   November 2018 in “JAAD case reports”
      Alopecia areata can sometimes appear as a straight line of hair loss instead of round patches.